Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials
- 19 December 2016
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 28 (4) , 898-899
Abstract
Molecular-targeted drugs, especially angiogenesis inhibitors, have improved outcomes in a variety of solid cancers in the metastatic, but not adjuvant, setting. Although various mechanisms have been proposed [1], the true reasons for this discrepancy between metastatic and adjuvant settings are not known. Renal cell cancer (RCC) is a highly vascular tumor and angiogenesis inhibitors such as sorafenib, sunitinib, pazopanib and axitinib have already shown clinical benefit in the metastatic setting. However, the efficacy of these agents in the adjuvant setting was until recently unknown. Two recently published phase 3 randomized controlled trials (RCTs)—the ASSURE trial [2] and the S-TRAC trial [3]—have tested sunitinib as an adjuvant treatment for high risk, resected RCC with discrepant results. Hence, we performed a meta-analysis to evaluate the benefit and risks of adjuvant treatment with sunitinib in this setting.Keywords
This publication has 5 references indexed in Scilit:
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyNew England Journal of Medicine, 2016
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialThe Lancet, 2016
- Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?Journal of Clinical Oncology, 2011
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor AngiogenesisCancer Cell, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009